In his comments, Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said, “The success of REVAC-B+TM bears testimony to our solid emphasis on R&D to develop vaccines that carry excellent safety and efficacy profiles. The Next Generation REVAC-Bmcf (Thiomersol and Cesium Chloride Free*) Recombinant Hepatitis-B Vaccine manufactured by us are cost-effective and address the safety concerns expressed by parents and members of the medical profession.” He added.
Bharat Biotech is a major supplier of the Cesium Chloride Free Hepatitis-B Vaccines, It has taken steps to ensure a smooth transition for customers from the traditional Hepatitis-B vaccine to the new preservative-free REVAC-Bmcf (Thiomersol and Cesium Chloride Free*) vaccine apart from effectively upgrading and optimizing production technologies to ensure the phasing out of thiomersol as preservative in some of BBIL products.
REVAC-Bmcf (Thiomersol and Cesium Chloride Free*) vaccine contains the same components utilized in BBIL’s previous Hepatitis-B vaccine, but now it is supplied preservative-free in a single-dose vial. Bharat Biotech had successfully manufactured a preservative-free pediatric vaccine of a highly reputed MNC on a contract basis and the product was exported to a regulated market in Far East.
A great success story of an Indian innovator who returned to India to make India the global centre for affordable heath care.